Search results
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Have you ever been tempted to take part in the TCS London Marathon? In 2022 the TCS London Marathon raised £58.3 million for charity so it’s a vital source of income.
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Whether you are a professional looking for practical information for yourself, or practical or emotional support for your clients, online, by phone or face-to-face, we're here to help. All of our services are free to access and offered in a range of accessible formats.
We are delighted to welcome Kathy Evans as our new Chair of Trustees.
We sat down to discuss what our volunteers got up to on Retina UK day.
Thursday 3 July, 7.00pm - 8.30pm - via Zoom - Please come and join our new facilitators Danielle and Perm for our latest Women's Peer Support Group meet up to discuss how we can manage our mental and physical Wellbeing.
Are you a parent or carer of a child or young person living with an inherited retinal dystrophy?
The latest podcast from Retina UK.
